agonistas del receptor glp-1 de péptido similar al glucagón tipo 1 (GLP-1) en el manejo del paciente con diabetes mellitus tipo 2. Una aproximación para el nefrólogo Agonistas Del Receptor Glp-1: Desde

Research groups developing methods must identify effective LC-MSn solutions to partner with sample preparation and software ecosystems to meet the challenging analytical requirements

Up to 39% of GLP-1 weight loss can come from lean mass

how far findings apply to non-diabetic, normal weight older adults remains unknown

For those who want to go deeper: JAMA Psychiatry (2025):- GLP-1 RAs & Mental Health Meta-Analysis: JAMA Psychiatry (2025):- Semaglutide & Alcohol Use Disorder RCT: eClinicalMedicine / The Lancet (2024):- 12-Month Neurological & Psychiatric Outcomes of Semaglutide: APA Monitor (2025):- Mental Health Effects of GLP-1 Drugs (accessible overview):

Zealand Pharma's agreement with Roche to jointly develop and commercialise an experimental amylin-based weight-loss treatment will create a strong obesity trea

Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released phase 2 trial results demonstrating 25% weight loss in half of people with #obesity